Abstract
Targeting telomerase-expressing cancer cells

Telomerase is the enzyme responsible for the maintenance of telomeres, which cap and protect the ends of chromosomes. Telomeres are made of tandem copies of a simple DNA repeat, (TTAGGG)n, which the enzyme telomerase synthesizes. In cells that lack telomerase, telomeres shorten with each round of cell division and this attrition eventually limits cellular lifespan
. [2] . This reactivation of telomerase stabilizes the telomeres and extends cellular lifespan. To escape senescence and gain cellular immortality, the great majority of cancers up-regulate telomerase. As a consequence, telomerase is detected in more than 85% of all cases of cancer [3, 4] , making the enzyme an attractive target for cancer therapeutics. In cancer cells, telomerase inhibition has been shown to lead to telomere shortening and, after sufficient cell divisions, this attrition can cause an uncapping of telomeres and induction of apoptosis [5, 6] . In this review, we discuss the biological and biochemical properties of telomerase, its use as a diagnostic and prognostic marker for cancers and its value as a target for cancer therapeutics.
After a finite number of cell divisions, cells without telomerase undergo a growth arrest termed replicative senescence. During cancer development, this limit poses an obstacle that tumour cells must overcome to become malignant. In the great majority of cancers, overcoming replicative senescence is achieved initially by inactivating important cell cycle checkpoints and eventually by upregulation of telomerase expression once telomeres have become critically short
Human telomeres act as a mitotic clock
Telomeres protect the ends of chromosomes from degradation, interchromosomal fusions and other forms of inadequate recombination [7, 8] [8, 9] . A second protective feature is the T-loop [10] . Although most of the telomere is made of duplex telomeric DNA, all telomeres end with a G-rich single-stranded 3Ј-overhang of 50 to 300 bases. Evidence suggests that this extension is sequestered into a large looping structure, termed a T-loop. Formation of this structure involves the looping of the telomere and the insertion of its 3Ј-telomeric overhang into upstream duplex telomeric DNA [8, 10] . It [2, 11, 12] .
Telomeres shorten because of problems associated with the replication of linear DNA molecules, the so-called 'end replication problems' [13] . When replication forks reach a telomere, problems are experienced at the levels of both the leading and lagging strand synthesis. On the lagging strand, internal priming by the last Okazaki fragment and removal of the RNA primer creates a gap of unreplicated DNA [1, 2] . On the leading strand, post-replication excision by the Apollo nuclease is needed to produce a single-stranded 3Ј-telomeric overhang that can serve as substrate for POT1 binding and T-loop formation [14, 15] . The net result is a loss of telomeric DNA repeats each time cells divide [1, 2] (Fig. 1) . In an intact cell, an uncapped telomere will be recognized as a ds-DNA break by DNA damage sensing mechanisms, the activation of which will induce ATM kinase activity, phosphorylation of p53 and up-regulation of cell cycle inhibitor p21 WAF1 [11, 12, 16, 17] [38] [39] [40] [41] . Oligonucleotides that can hybridize to the template region of hTR, as shown previously, can be used to inhibit telomerase (Fig. 2) [46, 48, 49] . [45, 48, [51] [52] [53] [54] . In mice bearing human tumour xenografts, GRN163L was determined to be well tolerated and efficacious. The maximum tolerated dose was 1000 mg/kg and telomerase inhibition could readily be detected with just 5 mg/kg [45] . [48] . [56] . Rare cells that fit this definition have been identified in a growing number of diseases, from haematological malignancies to brain, breast and pancreatic cancer [57] [58] [59] . Conventional therapies have been optimized to kill bulk tumour cells, not necessarily the cancer stem cells which tend to express multidrug resistance pumps [59, 60] . When these cancer stem cells divide in the presence of a telomerase inhibitor, their telomeres should shorten and this attrition would be expected to compromise the ability of these cells to self-renew (Fig. 3) . In recent studies, these predictions have been verified in the context of multiple myeloma as well as prostate, brain, breast and pancreatic cancer [61] [62] [63] [64] . Hence, cancer stem cells isolated from multiple myeloma specimens and cell lines showed reduced proliferation with 100-fold fewer colonies after 5 weeks of exposure to GRN163L [61] . Likewise, telomerase was inhibited and telomeres shortened in cancer stem cells after treatment of prostate cancer cells with GRN163L [64] . In addition, the abundance of cancer stem cells was reduced following GRN163L treatment of prostate, pancreatic and breast cancer cell lines [62, 64] [62, 63] . Taken together, these studies demonstrate broad anti-cancer stem cell activity of GRN163L, thereby confirming the rationale for using this drug to block disease recurrence after conventional cancer therapy. [66, 67] . [68] [69] [70] . A frequent problem that limits the broad applicability of cancer vaccines is the heterogeneous expression of the tumour antigen within a tumour. However, in the case of telomerase, the antigen is both universally expressed in cancers and critical for maintenance of the malignant phenotype [71] .
The effects of GRN163L have been investigated in cancer cells lines and in mice bearing human tumour xenografts. In a wide variety of cancer cell lines, GRN163L inhibited telomerase with IC50 in the nanomolar range [49]. In cancer cells chronically exposed to GRN163L, telomeres shorten with cell divisions and after a delay, a state of crisis is induced with evidence of chromosomal fusions, anaphase bridges and widespread apoptosis [45]. This inhibition of cellular growth by GRN163L has been reported in cancer cell lines of diverse origins, including multiple myeloma and tumours of the bladder, breast, liver, lung and stomach
Even when administered as a single agent, GRN163L could block the growth of implanted tumour cells. In mice carrying liver cancer xenografts, GRN163L alone inhibited tumour growth, in addition to sensitizing the tumour cells to conventional chemotherapy
In a xenograft model of lung cancer metastasis, administration of a single dose of GRN163L was sufficient to prevent the growth of lung metastases [45]. There are several possibilities for this rapid response to GRN163L treatment. First, most primary cancers have very short telomeres, which could include some that may already be critically short. This would lead to a rapid induction of apoptosis. However, in some instances what is observed in vitro and in vivo does not concur. Thus, it is possible that GRN163L may also be exerting telomerase-independent effects on tumour growth through mechanisms that remains poorly characterized. However, on the basis of these and other pre-clinical studies, GRN163L has entered clinical trials in patients afflicted with different forms of cancer. Phase I trials of GRN163L have just been completed in patients with chronic lymphocytic leukaemia, multiple myeloma and solid tumours (e.g. breast cancer and non-small cell lung cancer (NSCLC) [55]. From these trials, the bioavailability, pharmacokinetics, pharmacodynamics and tolerability over multiple cycles have been determined. Administered by intravenous infusions, GRN163L was found to have good safety profiles and excellent pharmacokinetics and biodistribution properties. At doses of 7.5 mg/kg and above, the level of exposure to GRN163L was higher than the exposure that was required in xenograft models
Telomerase-targeted immunotherapy
A different approach to target telomerase-expressing cancer cells is to use a vaccine to stimulate the patient's own immune system to attack tumour cells if they display hTERT peptides at their surface through major histocompatibility complex (MHC) presentation. Peptides displayed by MHC presentation are generated from within the cells by the limited proteolysis of cellular proteins, capture of the resulting peptides by MHC class I molecules, their transport to the plasma membrane and presentation at the surface by MHC class I molecules [65]. In telomerase-targeted immunotherapy, immune cells are exposed to a vaccine that consists of antigen-presenting cells that were either exposed to high levels of an immunogenic hTERT peptide or modified to overexpress an immunogenic fragment of hTERT. Once administered to a patient, the antigen-presenting cells elicit the activation and expansion of telomerase-specific cytotoxic T lymphocytes, which then can recognize and kill the telomerase-expressing tumour cells. Basic studies in human and murine systems have reported evidence of cytotoxic T cells that recognize dominant epitopes from hTERT and can kill tumour cells displaying these peptides
hTERT-based vaccines have also been reported to generate cytotoxic T cells against modified, low-affinity cryptic hTERT epitopes and these T cells protected animals against tumour challenges. In phase I clinical trials, tumour vaccines against hTERT have resulted in the induction of T-cell immune responses with minimal toxicities
Already, several hTERT-based vaccines have been developed but the most advanced vaccines are the GV1001 (GemVax) and GRN-VAC1 (Geron vaccine).
GV1001 is a 16-mer peptide from the active site of human TERT (aa 611-626) [68, 69] GRNVAC1 is a preparation of antigen-presenting cells transduced with mRNAs encoding a near full-length hTERT protein [71] . In this case, the antigen-presenting cells are autologous dendritic cells isolated from the patients' own tissues. Dendritic cells are a professional antigen-presenting cell whose main function is to process and display antigens [65] . In these cells, the hTERT fragment should be processed into a multitude of epitopes to elicit a polyclonal T-cell response, which could potentially recognize any hTERT peptide displayed by the patient's tumour [71] [85, 86] . Studies of these other second-generation viruses should determine if these oncolytic viruses have potential in the clinics for broad-spectrum cancer therapy.
Concluding remarks
The maintenance of telomeres by the cellular ribonucleoprotein enzyme telomerase is of well-documented importance for cancer [2, [87] [88] [89] [90] 
